Annual Report 2023
Department of Diagnostic Pathology
Yasushi Yatabe, Nobuyoshi Hiraoka, Taisuke Mori, Akihiko Yoshida, Masayuki Yoshida, Akiko Maeshima, Hiroshi Yoshida, Taiki Hashimoto, Junpei Hirokazu Sugino, Satsuki Kishikawa, Tomoaki Naka, Naoko Abeto, Shogo Nishino, Yuuto Kaimi, Ayaka Mitsui, Ayumi Sugitani, Shigeki Sekine, Naoki Kojima, Nami Yamamoto, Yuuka Takahashi, Sachiko Miura, Toshiko Sakaguchi, Kiyono Uchida, Shoichi Harada, Yumiko Sato, Sachiyo Hasegawa, Yuko Kashiwazaki, Nozomi Handa, Kimii Shiba
Introduction
The Department of Diagnostic Pathology is responsible for histological and cytological diagnoses and autopsies in the National Cancer Center Hospital. In 2023, the department consisted of 12 staff pathologists, 6 residents, and 16 pathology technologists, including 15 cytotechnologists. We accepted more than 30,000 specimens from the hospital and also provided a total of 256 pathological diagnoses via the pathology consultation.
The Team and What We Do
The accurate and precise histological and cytological diagnoses play a key role in cancer treatment provided in the hospital. The basis for diagnosis is gross observation and conventional hematoxylin-eosin staining of specimens, however, we also active layer form immunohistochemistry and special stain retrieval. In recent years, the detection of genetic abnormalities and expression of particular molecules have become more important in clinical practice, because several of the alterations have been used to select patients for molecular targeted therapy, treatment using immune checkpoint inhibitors and prediction of clinical outcomes. Although the number of pathological autopsies has remained stable over the past few years, the evaluation of the cause of death, the biological basis of the diseases and therapeutic effects from the autopsy specimens is indispensable to contribute to and improve the quality of medical care in our hospital. This year, we obtained 23,775 biopsy and surgical specimens, 11,043 cytological diagnoses, and 14 autopsies (Table 1). We consider the connection to the clinical departments to be very important; thus we held joint conferences regularly in addition to regular intradepartmental conferences and autopsy reviews.
We also encourage research work, which includes the studies for improving pathology diagnostics, clarifying biological features of diseases, and providing helpful findings for selecting therapeutic options.
Table 1. Numbers of specimens diagnosed in the department (2023)

Research Activities
Hepatobiliary Pancreas
We report that the presence of intraepithelial spreading (IES) is prognostic in the conventional extrahepatic cholangiocarcinoma cases, and the various clinicopathologic characteristics differ among cholangiocarcinomas arising in the hilar, upper, middle and lower bile ducts. IES characteristics differ among gallbladder, cystic, and ampullar carcinomas, and extrahepatic cholangiocarcinomas.
Gastrointestinal
We proposed a prognostic model for early gastric cancer through joint research with the Department of Gastric Surgery and the NCC Research Institute.
Skin tumors
We report a case of congenital dermatofibrosarcoma (DFSP) with fibrosarcomatous changes presenting with an atypical clinical behavior of repeated enlargement and shrinkage.
Head and neck and ocular tumors
To develop consensus recommendations on diagnostic criteria for histologically detected extranodal extension, we conducted a three-round modified Delphi with a group of 19 international pathology experts representing 15 national clinical research groups to generate consensus recommendations for histology detected extranodal extension diagnostic criteria. The expert panel strongly agreed on terminology and diagnostic features for histology detected extranodal extension and soft tissue metastasis. We participated as a consortium member of this expert panel to develop consensus recommendations. The correlation between LAT1 expression in tumor tissue and 18F-FBPA accumulation was examined in patients with head and neck cancer participating in a clinical trial of 18F-FBPA positron emission tomography (PET). 2 of 4 patients in whom 18F-FBPA accumulation did not match LAT1 expression intensity received boron neutron capture therapy (BNCT). Although 18F-FBPA accumulation and LAT1 expression intensity were moderately correlated, LAT1 expression may be a better predictor of BNCT response in patients in whom they did not match.
Gynecology
We performed central pathology review in the HER2-ADC clinical trial/PDX study of uterine carcinosarcoma. The utility of molecular classification of endometrial carcinoma was demonstrated with data from more than 1000 cases in Japan, and the prognostic ability of the FIGO2023 classification was also demonstrated in a Japanese cohort. We also published papers on the JCOG multicenter study of 148 cases of endometrial stromal sarcoma, expression of ADC targets (FRα, TROP2) in uterine carcinosarcoma, PDX in endometrial cancer, concordance between different clones of MMR-IHC, PDX in cervical gastric-type adenocarcinoma, and case reports of ovarian mucinous tumor showing gastric phenotype and ovarian mesonephric carcinoma.
Bone and soft tissue
We reported on a novel finding of blue lacy matrix in giant cell tumors of bone. We identified a novel keratin-positive fibrotic subset of extraskeletal myxoid chondrosarcoma. We showed that approximately 70% of spindle cell tumors with NTRK, BRAF, RAF1, or RET fusions expressed CD30, which has potential diagnostic significance. We reported novel KDM2B-rearranged soft tissue sarcomas that had overlapping phenotypes and DNA methylation status. A series of myxoid liposarcoma with nuclear pleomorphism was reported. Inflammatory rhabdomyoblastic tumors were comprehensively analyzed with clinicopathological and molecular methods in a series of 13 cases.
Brain tumors
We reported a case of central nervous system tumor with EP300::BCOR fusion, which should be considered in the differential diagnosis of supratentorial CNS tumors with ependymoma-like histological features.
Blood
We reported regarding pathogenesis of gastrointestinal follicular lymphomas based on histopathology and endoscopic findings. We published a review article: histologic transformation of follicular lymphoma: pathologists' viewpoint.
Urology
We participated in research: genomic and epigenomic integrative subtypes of renal cell carcinoma in a Japanese cohort.
Breast
We collaborated on an English statement for the Breast Cancer Society regarding the diagnosis and treatment of HER2-low-expressing breast cancer. Our research on radiofrequency ablation therapy for early-stage breast cancer, which we co-investigated, has been approved for insurance coverage. Additionally, we published papers on the role of MAP1B in triple-negative breast cancer, the clinicopathological characteristics of HER2-low-expressing breast cancer, and the changes in the expression of several PD-L1 antibodies in primary and metastatic lesions.
Respiratory
In collaboration with pathologists from the Pathology Committee of the World Conference on Lung Cancer, we launched a new study using JCOG0802, which compared the treatment outcomes of lobectomy and segmental resection, and began examining the histopathological significance of STAS. We also published several reviews, including the clinicopathological significance of STAS, and a molecular characteristic of KRAS mutations in lung cancer. We released expert consensus opinions on molecular analysis and treatment, including the perioperative period, for non-small cell lung cancer at ESMO, expert recommendations on MET-positive non-small cell cancer as ATORG (Asian Thoracic Oncology Research Group), and guidelines on MSI, NTRK, and TMB across organs from related academic societies in Japan, including the Japanese Society of Clinical Oncology and the Japanese Society of Medical Oncology.
Future Prospects
Our goal is to accomplish comprehensive pathological diagnosis, which is closely related to clinical practice, with the highest priority on medical safety. We will also train pathologists who are in short supply in Japan and provide training in pathology for tumor diagnosis. It is also important for us to develop research Hospital activities in cooperation with clinical departments and laboratories, and to apply biological abnormalities in tumors to diagnoses.
List of papers published in 2023
Journal
1. Watanabe T, Honma Y, Yonemori K, Sunami K, Yoshimoto S, Mori T. High-grade intraductal carcinoma of the parotid gland harboring CTNNA1::ALK rearrangement: Changes in genetic status using genetic testing during treatment with an ALK inhibitor. Head & neck, 46:E26-E31, 2024
2. Takamori S, Yatabe Y, Osoegawa A, Aokage K, Yoshioka H, Miyoshi T, Mimae T, Endo M, Hattori A, Yotsukura M, Isaka T, Isaka M, Maniwa T, Nakajima R, Watanabe SI. Rare but clinically important salivary gland-type tumor of the lung: A review. Japanese journal of clinical oncology, 54:121-128, 2024
3. Takeuchi C, Yamashita S, Liu YY, Takeshima H, Sasaki A, Fukuda M, Hashimoto T, Naka T, Ishizu K, Sekine S, Yoshikawa T, Hamada A, Yamamichi N, Fujishiro M, Ushijima T. Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation. Gut, 73:255-267, 2024
4. Ueno Y, Yoshida E, Nojiri S, Kato T, Ohtsu T, Takeshita T, Suzuki S, Yoshida H, Kato K, Itoh M, Notomi T, Usui K, Sozu T, Terao Y, Kawaji H, Kato H. Use of clinical variables for preoperative prediction of lymph node metastasis in endometrial cancer. Japanese journal of clinical oncology, 54:38-46, 2024
5. Kitadai R, Nishikawa T, Yoshida H, Mizoguchi C, Yamamoto K, Kato T, Yonemori K. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. Journal of gynecologic oncology, 35:e11, 2024
6. Kato MK, Fujii E, Asami Y, Momozawa Y, Hiranuma K, Komatsu M, Hamamoto R, Ebata T, Matsumoto K, Ishikawa M, Kohno T, Kato T, Yoshida H, Shiraishi K. Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer. Cancer science, 115:1646-1655, 2024
7. Kaimi Y, Takahashi Y, Taniguchi H, Ochi T, Makino H, Makita S, Iwaki N, Fukuhara S, Munakata W, Ogawa C, Izutsu K, Maeshima AM. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy. Virchows Archiv, 484:465-473, 2024
8. Yoshida A. NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumour: facts and controversies. Histopathology, 84:86-101, 2024
9. Grünewald TGP, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, Dermawan JK, Frezza AM, Italiano A, Jin JX, Le Loarer F, Martin-Broto J, Pecora A, Perez-Martinez A, Tam YB, Tirode F, Trama A, Pasquali S, Vescia M, Wortmann L, Wortmann M, Yoshida A, Webb K, Huang PH, Keller C, Antonescu CR. Translational Aspects of Epithelioid Sarcoma: Current Consensus. Clinical cancer research, 30:1079-1092, 2024
10. Noguchi R, Yoshimatsu Y, Sin Y, Ono T, Tsuchiya R, Yoshida H, Kiyono T, Yonemura Y, Kondo T. Establishment and characterization of NCC-PMP2-C1: a novel patient-derived cell line of pseudomyxoma peritonei with signet ring cells. Human cell, 37:511-522, 2024
11. Ono T, Noguchi R, Osaki J, Akiyama T, Adachi Y, Kojima N, Toda Y, Fukushima S, Yoshimatsu Y, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Human cell, 37:854-864, 2024
12. Osaki J, Noguchi R, Yanagihara K, Ono T, Adachi Y, Iwata S, Toda Y, Sekita T, Kobayashi E, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-ASPS2-C1: a novel patient-derived cell line of alveolar soft part sarcoma. Human cell, 37:865-873, 2024
13. Makiuchi S, Tian Y, Fujimoto M, Kuramoto J, Tsuda N, Ojima H, Gotoh M, Hiraoka N, Yoshida T, Kanai Y, Arai E. DNA methylation alterations of ADCY5, MICAL2, and PLEKHG2 during the developmental stage of cryptogenic hepatocellular carcinoma. Hepatology research, 54:284-299, 2024
14. Dacic S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, Berezowska S, Han Y, Chung JH, Beasley MB, Dongmei L, Hwang D, Mino-Kenudson M, Minami Y, Papotti M, Rekhtman N, Roden AC, Thunnissen E, Tsao MS, Yatabe Y, Yoshida A, Wang L, Hartman DJ, Jerome JA, Kadara H, Chou TY, Wistuba II. Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment. Journal of thoracic oncology, 19:273-284, 2024
15. Yatabe Y. Molecular pathology of non-small cell carcinoma. Histopathology, 84:50-66, 2024
16. Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S. Annual report of the Japanese Breast Cancer Registry for 2019. Breast cancer (Tokyo, Japan), 31:16-23, 2024
17. Iwamoto T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Konishi T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry. Breast cancer (Tokyo, Japan), 31:185-194, 2024
18. Shirai Y, Ueno T, Kojima S, Ikeuchi H, Kitada R, Koyama T, Takahashi F, Takahashi K, Ichimura K, Yoshida A, Sugino H, Mano H, Narita Y, Takahashi M, Kohsaka S. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma. Journal of neuro-oncology, 167:75-88, 2024
19. Yamashita K, Oka S, Yamada T, Mitsui K, Yamamoto H, Takahashi K, Shiomi A, Hotta K, Takeuchi Y, Kuwai T, Ishida F, Kudo SE, Saito S, Ueno M, Sunami E, Yamano T, Itabashi M, Ohtsuka K, Kinugasa Y, Matsumoto T, Sugai T, Uraoka T, Kurahara K, Yamaguchi S, Kato T, Okajima M, Kashida H, Akagi Y, Ikematsu H, Ito M, Esaki M, Kawai M, Yao T, Hamada M, Horimatsu T, Koda K, Fukai Y, Komori K, Saitoh Y, Kanemitsu Y, Takamaru H, Yamada K, Nozawa H, Takayama T, Togashi K, Shinto E, Torisu T, Toyoshima A, Ohmiya N, Kato T, Otsuji E, Nagata S, Hashiguchi Y, Sugihara K, Ajioka Y, Tanaka S. Clinicopathological features and prognosis of primary small bowel adenocarcinoma: a large multicenter analysis of the JSCCR database in Japan. Journal of gastroenterology, 59:376-388, 2024
20. Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan), 31:335-339, 2024
21. Hirasawa M, Kikuchi Y, Sato K, Yoshida A, Yamamoto A. FDG PET/CT and MRI Findings of Extraskeletal Myxoid Chondrosarcoma Showing a Nonmyxoid Cellular Variant. Clinical nuclear medicine, 49:434-437, 2024
22. Sugiyama M, Arakawa A, Iwata S, Tao K, Shirakawa N, Watanabe Y, Nakajima M, Yoshida A, Ishigaki K, Kawai A, Ogawa C. Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy. Pediatric blood & cancer, 71:e31036, 2024
23. Yoshida KI, Yoshida A. Sarcoma of the Lung and Mediastinum. Surgical pathology clinics, 17:243-255, 2024
24. Torasawa M, Yoshida T, Shiraishi K, Goto N, Ueno T, Ichikawa H, Yagishita S, Kohsaka S, Goto Y, Yatabe Y, Hamada A, Mano H, Ohe Y. Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report. JTO clinical and research reports, 5:100657, 2024
25. Sugino H, Satomi K, Mori T, Mukai Y, Honda-Kitahara M, Matsushita Y, Ichimura K, Narita Y, Yoshida A. High-grade neuroepithelial tumor with EP300::BCOR fusion and negative BCOR immunohistochemical expression: a case report. Brain tumor pathology, 40:133-141, 2023
26. Kawauchi D, Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Omura T, Yoshida A, Kubo Y, Igaki H, Ichimura K, Narita Y. Consulting a neurosurgeon upon initial medical assessment reduces the time to the first surgery and potentially contributes to improved prognosis for glioblastoma patients. Japanese journal of clinical oncology, 53:1027-1033, 2023
27. Murata T, Yoshida M, Shiino S, Watase C, Ogawa A, Shikata S, Hashiguchi H, Yoshii Y, Sugino H, Jimbo K, Maeshima A, Iwamoto E, Takayama S, Suto A. Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer. Breast cancer (Tokyo, Japan), 30:1054-1064, 2023
28. Miyakoshi J, Yazaki S, Shimoi T, Onishi M, Saito A, Kita S, Yamamoto K, Kojima Y, Sumiyoshi-Okuma H, Nishikawa T, Sudo K, Noguchi E, Murata T, Shiino S, Takayama S, Suto A, Fujiwara Y, Yoshida M, Yonemori K. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer. Virchows Archiv, 483:855-863, 2023
29. Shiino S, Tokura M, Nakayama J, Yoshida M, Suto A, Yamamoto Y. Investigation of Tumor Heterogeneity Using Integrated Single-Cell RNA Sequence Analysis to Focus on Genes Related to Breast Cancer-, EMT-, CSC-, and Metastasis-Related Markers in Patients with HER2-Positive Breast Cancer. Cells, 12:2286, 2023
30. Higashiyama M, Motoi N, Yotsukura M, Yoshida Y, Nakagawa K, Yagishita S, Shirasawa M, Yoshida T, Shiraishi K, Kohno T, Ohe Y, Watanabe SI. Clinicopathological characteristics and molecular analysis of lung cancer associated with ciliated muconodular papillary tumor/bronchiolar adenoma. Pathology international, 73:188-197, 2023
31. Aoki K, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Nishizawa T, Fukuda H, Ohashi K, Arai K, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Maruyama T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Mizuno H, Tsunoda H, Ochiai A. Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations. Cancer research communications, 3:1026-1040, 2023
32. Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer. British journal of cancer, 129:2003-2013, 2023
33. Haga Y, Sakamoto Y, Kajiya K, Kawai H, Oka M, Motoi N, Shirasawa M, Yotsukura M, Watanabe SI, Arai M, Zenkoh J, Shiraishi K, Seki M, Kanai A, Shiraishi Y, Yatabe Y, Matsubara D, Suzuki Y, Noguchi M, Kohno T, Suzuki A. Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma. Nature communications, 14:8375, 2023
34. Nishimatsu K, Matsumoto Y, Kashima J, Imabayashi T, Uchimura K, Furuse H, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Tsuchida T, Ohe Y, Yatabe Y. Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma. Translational lung cancer research, 12:1245-1255, 2023
35. Hayashi T, Takasawa K, Yoshikawa T, Hashimoto T, Sekine S, Wada T, Yamagata Y, Suzuki H, Abe S, Yoshinaga S, Saito Y, Kouno N, Hamamoto R. A discrimination model by machine learning to avoid gastrectomy for early gastric cancer. Annals of gastroenterological surgery, 7:913-921, 2023
36. Terasaki M, Tsuruoka K, Tanaka T, Maeda H, Shibata M, Miyashita K, Kanemitsu Y, Sekine S, Takahashi M, Yagishita S, Hamada A. Fucoxanthin Inhibits Development of Sigmoid Colorectal Cancer in a PDX Model With Alterations of Growth, Adhesion, and Cell Cycle Signals. Cancer genomics & proteomics, 20:686-705, 2023
37. Kawasaki Y, Hijioka S, Nagashio Y, Maruki Y, Ohba A, Takeshita K, Takasaki T, Agarie D, Hagiwara Y, Hara H, Okamoto K, Yamashige D, Kondo S, Morizane C, Ueno H, Mizui T, Takamoto T, Nara S, Ban D, Esaki M, Tamada K, Hiraoka N, Saito Y, Okusaka T. Efficacy of endoscopic ultrasound-guided tissue acquisition for solid pancreatic lesions 20 mm or less in diameter suspected as neuroendocrine tumors or requiring differentiation. Journal of gastroenterology, 58:693-703, 2023
38. Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. Journal of clinical oncology, 41:2789-2799, 2023
39. Yoshida H, Mizoguchi C, Saito A, Kitadai R, Yamamoto K, Nishikawa T, Kato T, Yonemori K. Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection. Annals of diagnostic pathology, 65:152150, 2023
40. Saito A, Nishikawa T, Yoshida H, Mizoguchi C, Kitadai R, Yamamoto K, Yazaki S, Kojima Y, Ishikawa M, Kato T, Yonemori K. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma. Gynecologic oncology, 176:115-121, 2023
41. Kojima Y, Yoshida H, Okuya T, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Shimoi T, Tamura K, Tanase Y, Uno M, Ishikawa M, Arakaki M, Ichikawa H, Yagishita S, Hamada A, Fujiwara Y, Yonemori K, Kato T. Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma. Gynecologic oncology reports, 50:101302, 2023
42. Sugino H, Iwata S, Satomi K, Mori T, Nobusawa S, Nagashima T, Matsushita Y, Yatabe Y, Ichimura K, Kawai A, Yoshida A. Keratin-positive fibrotic extraskeletal myxoid chondrosarcoma: a close mimic of myoepithelial tumour. Histopathology, 82:937-945, 2023
43. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Kosako H, Yoshida A, Ohtori S, Kawai A, Kondo T. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor. Expert review of proteomics, 20:109-119, 2023
44. Okumura M, Ogata D, Namikawa K, Takahashi A, Nishimura Y, Mori T, Yoshida H, Akiyama M, Yamazaki N. Adenosquamous carcinoma of the Bartholin gland treated with surgery and radiotherapy. European journal of dermatology, 33:309-311, 2023
45. Fukuta T, Tanaka T, Hashimoto T, Isahaya K, Kubo Y, Yamano Y, Satomi K, Hiraoka N, Shirakawa N, Arakawa A, Ogawa C, Nishimura N, Aoki J, Ito A, Inamoto Y, Kim SW, Fukuda T. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases. International journal of hematology, 117:933-940, 2023
46. Tao K, Yamazaki F, Kubo T, Sunami K, Kumamoto T, Arakawa A, Sugiyama M, Watanabe Y, Nakajima M, Shirakawa N, Tanimura K, Koyama T, Hirata M, Sudo K, Tanabe N, Watanabe T, Yoshida T, Kitami M, Yoshida A, Yatabe Y, Nakano Y, Ohira M, Kamijo T, Nakazawa A, Kato M, Ichimura K, Kohno T, Yamamoto N, Hishiki T, Ichikawa H, Ogawa C. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project. JCO precision oncology, 7:e2200266, 2023
47. Motoi T, Hirata M, Kukita Y, Satomi K, Tamura H, Adachi S, Matsushita Y, Horiguchi SI, Hishima T, Ikegami M, Okuma T, Tao K, Arakawa A, Ogawa C, Matsuda K, Ichimura K, Nakamura H, Mori T, Yoshida A. KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated Sarcoma. Modern pathology, 36:100317, 2023
48. Miyazaki B, Ueno T, Sugiyama M, Kojima S, Arakawa A, Tao K, Tanimura K, Shiraishi K, Yagishita S, Kohsaka S, Kato M, Kiyokawa N, Goto Y, Yatabe Y, Hamada A, Mano H, Ogawa C, Tanaka Y. Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia. NPJ precision oncology, 7:132, 2023
49. Okuma HS, Yoshida H, Kobayashi Y, Arakaki M, Mizoguchi C, Inagaki L, Voon PJ, Malik Bin Ismail A, Fen Soo Hoo H, Yusak S, Severino B Imasa M, Nguyen Huy T, Thai Anh T, Kohsaka S, Mano H, Yonemori K, Nakamura K, Yatabe Y. Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia. Cancer science, 114:2664-2673, 2023
50. Yagishita S, Nishikawa T, Yoshida H, Shintani D, Sato S, Miwa M, Suzuki M, Yasuda M, Ogitani Y, Jikoh T, Yonemori K, Hasegawa K, Hamada A. Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy. Clinical cancer research, 29:2239-2249, 2023
51. Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study. Cancer discovery, 13:1814-1825, 2023
52. Shimamoto Y, Takeuchi Y, Ishiguro S, Nakatsuka SI, Yunokizaki H, Ezoe Y, Nakajima T, Tanaka K, Ishihara R, Takayama T, Yoshida T, Sugano K, Mutoh M, Ishikawa H. Genotype-phenotype correlation for extracolonic aggressive phenotypes in patients with familial adenomatous polyposis. Cancer science, 114:4596-4606, 2023
53. Hojo K, Furuta T, Komaki S, Yoshikane Y, Kikuchi J, Nakamura H, Ide M, Shima S, Hiyoshi Y, Araki J, Tanaka S, Ozono S, Yoshida A, Nobusawa S, Morioka M, Nishikomori R. Systemic inflammation caused by an intracranial mesenchymal tumor with a EWSR1::CREM fusion presenting associated with IL-6/STAT3 signaling. Neuropathology, 43:244-251, 2023
54. Shimizu Y, Suzuki M, Akiyama O, Ogino I, Matsushita Y, Satomi K, Yanagisawa S, Ohno M, Takahashi M, Miyakita Y, Narita Y, Ichimura K, Kondo A. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma. Brain tumor pathology, 40:93-100, 2023
55. Nikaido M, Takimoto T, Sakurai T, Hoki M, Minamiguchi S, Nakajima T, Torishima M, Nishigori T, Obama K, Koyama Y, Chiba T, Ushiama M, Gotoh M, Teramura M, Takeda H, Shimizu T, Seno H. Gastric juvenile polyposis syndrome with inflammatory changes in the intervening mucosa. Pathology international, 73:566-569, 2023
56. Noguchi R, Yoshimatsu Y, Sin Y, Ono T, Tsuchiya R, Yoshida H, Kiyono T, Yonemura Y, Kondo T. Correction: Noguchi et al. Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei. J. Pers. Med. 2022, 12, 258. Journal of personalized medicine, 13:2023